BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema - Seite 4
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
Lesen Sie auch